97 related articles for article (PubMed ID: 21291756)
1. Chronic kidney disease as a cardiovascular risk state and considerations for the use of statins.
McCullough PA; Rocher LR; Nistala R; Whaley-Connell A
J Clin Lipidol; 2008 Oct; 2(5):318-27. PubMed ID: 21291756
[TBL] [Abstract][Full Text] [Related]
2. Statin therapy in renal disease: harmful or protective?
McCullough PA; Rocher LR
Curr Atheroscler Rep; 2007 Jan; 9(1):18-24. PubMed ID: 17169242
[TBL] [Abstract][Full Text] [Related]
3. Statin therapy in renal disease: harmful or protective?
McCullough PA; Rocher LR
Curr Diab Rep; 2007 Dec; 7(6):467-73. PubMed ID: 18255012
[TBL] [Abstract][Full Text] [Related]
4. Effects of lipid-lowering therapy on reduction of cardiovascular events in patients with end-stage renal disease requiring hemodialysis.
Marrs JC; Saseen JJ
Pharmacotherapy; 2010 Aug; 30(8):823-9. PubMed ID: 20653359
[TBL] [Abstract][Full Text] [Related]
5. Pleiotropic effects of statins: evidence against benefits beyond LDL-cholesterol lowering.
Pedersen TR
Am J Cardiovasc Drugs; 2010; 10 Suppl 1():10-7. PubMed ID: 21391729
[TBL] [Abstract][Full Text] [Related]
6. [Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment].
Cases Amenós A; Goicoechea Diezhandiño M; de Alvaro Moreno F
Nefrologia; 2008; 28 Suppl 3():39-48. PubMed ID: 19018737
[TBL] [Abstract][Full Text] [Related]
7. The efficacy and safety of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors in chronic kidney disease, dialysis, and transplant patients.
Olyaei A; Greer E; Delos Santos R; Rueda J
Clin J Am Soc Nephrol; 2011 Mar; 6(3):664-78. PubMed ID: 21393488
[TBL] [Abstract][Full Text] [Related]
8. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
Mora S; Ridker PM
Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935
[TBL] [Abstract][Full Text] [Related]
9. Pleiotropic effects of statins: evidence for benefits beyond LDL-cholesterol lowering.
Marzilli M
Am J Cardiovasc Drugs; 2010; 10 Suppl 1():3-9. PubMed ID: 21391728
[TBL] [Abstract][Full Text] [Related]
10. Statin treatment for dyslipidemia in chronic kidney disease and renal transplantation: a review of the evidence.
Kanbay M; Turgut F; Covic A; Goldsmith D
J Nephrol; 2009; 22(5):598-609. PubMed ID: 19809992
[TBL] [Abstract][Full Text] [Related]
11. Statins and cardiovascular risk reduction in patients with chronic kidney disease and end-stage renal failure.
Baber U; Toto RD; de Lemos JA
Am Heart J; 2007 Apr; 153(4):471-7. PubMed ID: 17383281
[TBL] [Abstract][Full Text] [Related]
12. The role of statins in chronic kidney disease.
Kalaitzidis RG; Elisaf MS
Am J Nephrol; 2011; 34(3):195-202. PubMed ID: 21791915
[TBL] [Abstract][Full Text] [Related]
13. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
Hausenloy DJ; Yellon DM
Heart; 2008 Jun; 94(6):706-14. PubMed ID: 18480348
[TBL] [Abstract][Full Text] [Related]
14. Effect of pravastatin in people with diabetes and chronic kidney disease.
Tonelli M; Keech A; Shepherd J; Sacks F; Tonkin A; Packard C; Pfeffer M; Simes J; Isles C; Furberg C; West M; Craven T; Curhan G
J Am Soc Nephrol; 2005 Dec; 16(12):3748-54. PubMed ID: 16251235
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us?
Fabbri G; Maggioni AP
Adv Ther; 2009 May; 26(5):469-87. PubMed ID: 19444394
[TBL] [Abstract][Full Text] [Related]
16. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
17. HMG-CoA reductase inhibitors in chronic kidney disease.
Olyaei A; Steffl JL; MacLaughlan J; Trabolsi M; Quadri SP; Abbasi I; Lerma E
Am J Cardiovasc Drugs; 2013 Dec; 13(6):385-98. PubMed ID: 23975627
[TBL] [Abstract][Full Text] [Related]
18. Intensive statin therapy for Indians: Part-I. Benefits.
Enas EA; Pazhoor HC; Kuruvila A; Vijayaraghavan K
Indian Heart J; 2011; 63(3):211-27. PubMed ID: 22734339
[TBL] [Abstract][Full Text] [Related]
19. Models for describing relations among the various statin drugs, low-density lipoprotein cholesterol lowering, pleiotropic effects, and cardiovascular risk.
Robinson JG
Am J Cardiol; 2008 Apr; 101(7):1009-15. PubMed ID: 18359323
[TBL] [Abstract][Full Text] [Related]
20. The effect of intensified lipid-lowering therapy on long-term prognosis in patients with peripheral arterial disease.
Feringa HH; Karagiannis SE; van Waning VH; Boersma E; Schouten O; Bax JJ; Poldermans D
J Vasc Surg; 2007 May; 45(5):936-43. PubMed ID: 17360142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
